The estimated Net Worth of Daniel Paul Regan is at least $237 millier dollars as of 30 January 2015. Daniel Regan owns over 9,847 units of Intercept Pharmaceuticals Inc stock worth over $211,109 and over the last 12 years Daniel sold ICPT stock worth over $25,768.
Daniel has made over 5 trades of the Intercept Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Daniel exercised 9,847 units of ICPT stock worth $371,133 on 30 January 2015.
The largest trade Daniel's ever made was exercising 20,000 units of Intercept Pharmaceuticals Inc stock on 5 March 2014 worth over $753,800. On average, Daniel trades about 3,465 units every 30 days since 2013. As of 30 January 2015 Daniel still owns at least 11,111 units of Intercept Pharmaceuticals Inc stock.
You can see the complete history of Daniel Regan stock trades at the bottom of the page.
Daniel's mailing address filed with the SEC is 1 Marina Park Drive, Boston, MA 02210, USA.
Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over $1,530,243,701 worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth $77,118,364 . The most active insiders traders include Srinivas Akkaraju, Jonathan Silverstein et Francesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,114,673. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth $5,017,290.
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include: